Estudo randomizado | Entre prematuros com idade gestacional menor que 30 semanas e entubados por pelo menos 7 e nascidos de 14 a 28 dias, hidrocortisona não melhorou a sobrevida sem displasia broncopulmonar.

Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Ver também: Visual Abstract

Conteúdos relacionados:

Randomized Trial: Effect of Hydrocortisone on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation

Systematic Review: Late (after 6 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Systematic Review: Early (started within six days) systemic postnatal corticosteroids for preventing bronchopulmonary dysplasia in preterm infants.

State of the Art Review: Diagnosis and management of bronchopulmonary dysplasia.

M-A: Assessment of postnatal corticosteroids for the prevention of bronchopulmonary dysplasia in preterm neonates

ERS Guideline on Long-term Management of Children with Bronchopulmonary Dysplasia

Comentário no Twitter

In this trial involving preterm infants, there was little difference in survival without bronchopulmonary dysplasia or in the occurrence of neurodevelopmental impairment with hydrocortisone as compared with placebo. https://t.co/wzGQ1gohjA pic.twitter.com/yfrIaG3JLv

— NEJM (@NEJM) March 23, 2022